ME02169B - Derivat 1,2,4-triazolona - Google Patents
Derivat 1,2,4-triazolonaInfo
- Publication number
- ME02169B ME02169B MEP-2015-99A MEP9915A ME02169B ME 02169 B ME02169 B ME 02169B ME P9915 A MEP9915 A ME P9915A ME 02169 B ME02169 B ME 02169B
- Authority
- ME
- Montenegro
- Prior art keywords
- cerebral
- disease
- compound
- diseases
- triazolone
- Prior art date
Links
- MDTUWBLTRPRXBX-UHFFFAOYSA-N 1,2,4-triazol-3-one Chemical class O=C1N=CN=N1 MDTUWBLTRPRXBX-UHFFFAOYSA-N 0.000 title abstract 2
- 102000004136 Vasopressin Receptors Human genes 0.000 abstract 2
- 108090000643 Vasopressin Receptors Proteins 0.000 abstract 2
- 206010008118 cerebral infarction Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010048962 Brain oedema Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract 1
- 208000006752 brain edema Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Predmetni pronalazak se odnosi najedinjenje koje ima 1,2,4-triazolonski skelet, a koje pokazuje antagonističkodejstvo na arginin-vazopresinski receptor (AVP)V1b, kao i na farmaceutskipreparat koji sadrži navedeno jedinjenje kao aktivni sastojak, konkretnije, naterapeutsko ili preventivno sredstvo za bolesti kao što su poremećajiraspoloženja, anksiozni poremećaj, šizofrenija, Alchajmerova bolest,Parkinsonova bolest, Hantingtonova horeja, poremećaji u ishrani, hipertenzija,gastrointestinalne bolesti, zavisnost od lekova, epilepsija, cerebralniinfarkt, cerebralna ishemija, cerebralni edem, povrede glave, zapaljenje,bolesti koje se dovode u vezu sa imunim sistemom i alopecija.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010224233 | 2010-10-01 | ||
JP2011054500 | 2011-03-11 | ||
EP20110829344 EP2623499B1 (en) | 2010-10-01 | 2011-09-30 | 1,2,4-triazolone derivative |
PCT/JP2011/072556 WO2012043791A1 (ja) | 2010-10-01 | 2011-09-30 | 1,2,4-トリアゾロン誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
ME02169B true ME02169B (me) | 2015-10-20 |
Family
ID=45893228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2015-99A ME02169B (me) | 2010-10-01 | 2011-09-30 | Derivat 1,2,4-triazolona |
Country Status (29)
Country | Link |
---|---|
US (1) | US9193695B2 (me) |
EP (1) | EP2623499B1 (me) |
JP (1) | JP5787237B2 (me) |
KR (1) | KR101820185B1 (me) |
CN (1) | CN103119028B (me) |
AU (1) | AU2011308403B2 (me) |
BR (1) | BR112013007389B1 (me) |
CA (1) | CA2811192C (me) |
CY (1) | CY1116518T1 (me) |
DK (1) | DK2623499T3 (me) |
ES (1) | ES2536084T3 (me) |
HK (1) | HK1182109A1 (me) |
HR (1) | HRP20150462T1 (me) |
HU (1) | HUE025729T2 (me) |
IL (1) | IL225091A (me) |
ME (1) | ME02169B (me) |
MX (1) | MX2013003633A (me) |
MY (1) | MY165626A (me) |
NZ (1) | NZ608729A (me) |
PL (1) | PL2623499T3 (me) |
PT (1) | PT2623499E (me) |
RS (1) | RS54112B1 (me) |
RU (1) | RU2566754C2 (me) |
SG (1) | SG189156A1 (me) |
SI (1) | SI2623499T1 (me) |
SM (1) | SMT201500166B (me) |
TW (1) | TWI518075B (me) |
WO (1) | WO2012043791A1 (me) |
ZA (1) | ZA201302651B (me) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2772482E (pt) | 2011-10-27 | 2016-06-03 | Taisho Pharmaceutical Co Ltd | Derivados de azole |
JP5929812B2 (ja) * | 2012-03-30 | 2016-06-08 | 大正製薬株式会社 | 1,2,4−トリアゾロン誘導体を含有する医薬 |
TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
AU2014254261B2 (en) | 2013-04-15 | 2017-11-09 | Fmc Corporation | Fungicidal amides |
JP6387669B2 (ja) * | 2013-04-26 | 2018-09-12 | 大正製薬株式会社 | アゾール誘導体を含有する医薬 |
CA3022755A1 (en) * | 2016-05-03 | 2017-11-09 | Carsten Schmeck | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
US9988367B2 (en) * | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2076257A1 (en) * | 1991-09-13 | 1993-03-14 | Jan Heeres | 4-¬4-¬4-(4-hydroxyphenyl)-1- piperazinyl|phenyl|-5-methyl-3h -1,2,4-triazol-3-one derivatives |
JP2000063363A (ja) | 1998-08-12 | 2000-02-29 | Yamanouchi Pharmaceut Co Ltd | 新規なトリアゾール誘導体 |
FR2792314B1 (fr) * | 1999-04-15 | 2001-06-01 | Adir | Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2804114B1 (fr) | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
EP1347758A1 (en) * | 2000-12-26 | 2003-10-01 | Ranbaxy Laboratories, Ltd. | Azole compounds as anti-fungals agents |
AU2003288640A1 (en) * | 2002-12-31 | 2004-07-22 | Pfizer Products Inc. | Benzamide inhibitors of the p2x7 receptor |
CN100404511C (zh) * | 2003-04-28 | 2008-07-23 | 安斯泰来制药有限公司 | 4,4-二氟-1,2,3,4-四氢-5h-1-苯并氮杂䓬衍生物或其盐 |
EP1659121A4 (en) | 2003-08-28 | 2008-11-26 | Taisho Pharmaceutical Co Ltd | D RIV OF 1,3-DIHYDRO-2H-INDOL-2-ONE |
US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
GB0329693D0 (en) * | 2003-12-22 | 2004-01-28 | Pfizer Ltd | Compounds useful in therapy |
CA2551038C (en) * | 2003-12-22 | 2010-04-27 | Pfizer Inc. | Triazole derivatives as vasopressin antagonists |
US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
AU2005219791B2 (en) * | 2004-03-05 | 2011-06-09 | Msd K.K. | Diaryl-substituted five-membered heterocycle derivative |
BRPI0509275A (pt) | 2004-03-26 | 2007-09-04 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método de tratamento e/ou profilaxia de enfermidades que são moduladas por agonistas de lxr(alfa) e/ou lxr(beta) e utilização dos mesmos |
EP1742932A1 (en) | 2004-04-28 | 2007-01-17 | Pfizer Limited | 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor |
AR052342A1 (es) * | 2004-12-21 | 2007-03-14 | Janssen Pharmaceutica Nv | Derivados sustituidos de triazolona,tetrazolona e imidazolona con actividad selectiva antagonista de alfa2c-adenoreceptores |
TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
CN104922117A (zh) | 2005-03-22 | 2015-09-23 | 阿泽范药品公司 | 用于治疗月经前病症的β-内酰氨基链烷酸 |
MX2007015427A (es) * | 2005-06-07 | 2008-04-16 | Pharmacopeia Inc | Inhibidores de azinona y diazinona v3 para depresion y trastornos de estres. |
WO2007109098A2 (en) | 2006-03-16 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS |
ES2355951T3 (es) * | 2006-03-24 | 2011-04-01 | EISAI R&D MANAGEMENT CO., LTD. | Derivados de triazolona. |
DE102006024024A1 (de) * | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
US8119676B2 (en) | 2006-08-26 | 2012-02-21 | Abbott GmbH & Co. HG | Substituted benzimidazolone derivatives, medicaments comprising them and their use |
JP5271909B2 (ja) | 2006-09-11 | 2013-08-21 | エム・エス・ディー・オス・ベー・フェー | 2−(1−オキソ−1h−イソキノリン−2−イル)アセトアミド誘導体 |
CA2663161C (en) | 2006-09-11 | 2014-10-28 | N.V. Organon | Quinazolinone and isoquinolinone acetamide derivatives |
DE102007002715A1 (de) * | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
JP2010229035A (ja) | 2007-08-01 | 2010-10-14 | Taisho Pharmaceutical Co Ltd | ピリドピリミジン−4−オン誘導体 |
EP2183227B1 (en) * | 2007-08-07 | 2014-09-24 | Prosarix Limited | 1,2,4-triazole derivatives as serotonergic modulators |
WO2009130232A1 (en) * | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors |
WO2009130231A1 (en) | 2008-04-24 | 2009-10-29 | Glaxo Group Limited | Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists |
JP5369721B2 (ja) | 2009-01-30 | 2013-12-18 | 大正製薬株式会社 | ピリドピリミジン−4−オン誘導体 |
DE102009013642A1 (de) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylalaninderivate und deren Verwendung |
JP2013075830A (ja) | 2010-02-03 | 2013-04-25 | Taisho Pharmaceutical Co Ltd | キノリン誘導体 |
US9187466B2 (en) | 2010-02-27 | 2015-11-17 | Bayer Intellectual Property Gmbh | Bisaryl-bonded aryltriazolones and use thereof |
PT2772482E (pt) * | 2011-10-27 | 2016-06-03 | Taisho Pharmaceutical Co Ltd | Derivados de azole |
-
2011
- 2011-09-30 HU HUE11829344A patent/HUE025729T2/en unknown
- 2011-09-30 SI SI201130476T patent/SI2623499T1/sl unknown
- 2011-09-30 TW TW100135601A patent/TWI518075B/zh active
- 2011-09-30 CN CN201180046853.3A patent/CN103119028B/zh active Active
- 2011-09-30 ES ES11829344.8T patent/ES2536084T3/es active Active
- 2011-09-30 RS RS20150442A patent/RS54112B1/en unknown
- 2011-09-30 DK DK11829344.8T patent/DK2623499T3/da active
- 2011-09-30 AU AU2011308403A patent/AU2011308403B2/en active Active
- 2011-09-30 KR KR1020137006784A patent/KR101820185B1/ko active IP Right Grant
- 2011-09-30 WO PCT/JP2011/072556 patent/WO2012043791A1/ja active Application Filing
- 2011-09-30 SG SG2013023304A patent/SG189156A1/en unknown
- 2011-09-30 MY MYPI2013001115A patent/MY165626A/en unknown
- 2011-09-30 PL PL11829344T patent/PL2623499T3/pl unknown
- 2011-09-30 NZ NZ608729A patent/NZ608729A/en unknown
- 2011-09-30 BR BR112013007389-6A patent/BR112013007389B1/pt active IP Right Grant
- 2011-09-30 CA CA2811192A patent/CA2811192C/en active Active
- 2011-09-30 RU RU2013120338/04A patent/RU2566754C2/ru active
- 2011-09-30 EP EP20110829344 patent/EP2623499B1/en active Active
- 2011-09-30 MX MX2013003633A patent/MX2013003633A/es active IP Right Grant
- 2011-09-30 US US13/824,174 patent/US9193695B2/en active Active
- 2011-09-30 JP JP2012536579A patent/JP5787237B2/ja active Active
- 2011-09-30 PT PT118293448T patent/PT2623499E/pt unknown
- 2011-09-30 ME MEP-2015-99A patent/ME02169B/me unknown
-
2013
- 2013-03-07 IL IL225091A patent/IL225091A/en active IP Right Grant
- 2013-04-12 ZA ZA2013/02651A patent/ZA201302651B/en unknown
- 2013-08-13 HK HK13109464.3A patent/HK1182109A1/zh unknown
-
2015
- 2015-04-29 HR HRP20150462TT patent/HRP20150462T1/hr unknown
- 2015-07-09 SM SM201500166T patent/SMT201500166B/xx unknown
- 2015-07-13 CY CY20151100611T patent/CY1116518T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ME02402B (me) | Derivati azola | |
ME02169B (me) | Derivat 1,2,4-triazolona | |
ME02433B (me) | Nitrooksiderivati prostaglandina | |
EA201591537A1 (ru) | Производные бензотиофена и композиции, их содержащие, в качестве селективных супрессоров эстрогеновых рецепторов | |
WO2016106106A3 (en) | Fused heteroaryl derivatives as orexin receptor antagonists | |
ECSP10010226A (es) | Compuestos derivados de amina para tratar enfermedades y trastornos oftálmicos | |
GT201400016A (es) | Indazoles | |
TR201909277T4 (tr) | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. | |
BR112014001880A2 (pt) | derivados de carboxamida e ureia contendo pirazol heteroaromáticos substituídos como ligantes de receptor vaniloide | |
WO2014106238A8 (en) | Heterocyclic compounds and methods of use thereof | |
UA104869C2 (uk) | Фармацевтичні композиції, що містять ліганди рецептора дофаміну | |
MX357780B (es) | Derivados policíclicos, proceso para su preparación y su uso farmacéutico. | |
CY1118848T1 (el) | Ενωσεις 1,3-οξαζολιδινης ή 1,3-οξαζινανης ως ανταγωνιστες υποδοχεα ορεξινης | |
EA200970760A1 (ru) | Быстро диссоциирующие антагонисты рецептора 2 дофамина | |
MA35816B1 (fr) | Dérivés d'aniline, leur préparation et leur application thérapeutique | |
UA117154C2 (uk) | Антагоністи s1p3 | |
EA201170256A1 (ru) | Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d2 рецепторов дофамина | |
MX2015008733A (es) | Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma. | |
CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
JO2642B1 (en) | Dopamine 2 receptor antagonists are rapidly hydrolyzed | |
NZ707946A (en) | Hydantoin derivative | |
MX2009011414A (es) | Derivados de piridina como antagonistas del receptor de dopamina 2 de disociacion rapida. | |
NZ712341A (en) | A crystalline form of an anxiolytic compound | |
IN2013MU01177A (me) | ||
MX2014000855A (es) | Moduladores receptores de glucagon de quinolinilo. |